Inspyr Therapeutics, Inc. Stock Price - NSPX

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Inspyr Therapeutics, Inc. (QB) NSPX Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0.0001 +3.85% 0.0027 0.003 0.0022 0.0027 0.0026 16:00:04
Bid Price Ask Price Spread Spread % News
0.0025 0.0028 0.0003 10.71% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
65 6,421,755 $ 0.0027 $ 17.45k 5.9M 0.0000 - 0.0030
Last Trade Time Type Quantity Stock Price Currency
15:59:06 150,000 $0.00 USD

Inspyr Therapeutics, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 25.86k 9.58M $ -3.56M - -0.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Inspyr Therapeutics, Inc. (QB) News

Latest NSPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NSPX Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week00.00300.000006M0--
1 Month00.00300.000006M0--
3 Months00.00300.000006M0--
6 Months00.00300.000006M0--
1 Year00.00300.000006M0--
3 Years00.00300.000006M0--
5 Years00.00300.000006M0--

Inspyr Therapeutics, Inc. (QB) Description

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.


Your Recent History
USOTC
NSPX
Inspyr The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.